THERAPEUTIC EXOSOMES AND METHOD OF PRODUCING THEM
The invention provides improved methods, compositions, uses and kits relating to exosomes isolated from cells and therapeutic compositions and methods of using those exosomes. In one embodiment, the exosomes are loaded with one or more molecules to provide a desired therapeutic effect.
1 . An exosome loaded with one or more molecules to provide a therapeutic effect.
2 . The exosome of claim 1 , wherein the exosome is isolated from clonal progenitor cell line 30 MV2-14, 30-MV2-4, E69, or RPI-MV2-8.
3 . The exosome of claim 1 , wherein the exosome is capable of accelerating wound healing.
4 . The exosome of claim 1 , wherein the wound healing is measured by a migration assay and the percent of relative wound density is accelerated over that of a control without added exosomes.
5 . The exosome of claim 1 , wherein the exosome is capable of accelerating angiogenesis.
6 . The exosome of claim 5 , wherein the angiogenesis is observed by tube formation within 14 days.
7 . The exosome of claim 1 , wherein the exosome is capable of reducing the effects of aging.
8 . The exosome of claim 1 , wherein the exosome is capable of cardioprotection.
9 . The exosome of claim 1 , wherein the exosome is capable of neuroprotection.
10 . The exosome of claim 1 , wherein the exosome is capable of cardiac repair or regeneration.
11 . The exosome of claim 1 , wherein the exosome is capable of regulating immune activity.
12 . The exosome of claim 1 , wherein the exosome is capable of increasing vaccine outcome or vaccine potency.
13 . The exosome of claim 1 , wherein the exosome is loaded with miRNA.
14 . The exosome of claim 13 , wherein the miRNA is loaded via electroporation.
15 . The exosome of claim 1 , wherein the exosome is capable of providing epigenetic rejuvenation.
16 . The exosome of claim 1 , wherein the exosome is capable of modulating senolytic activity.
17 . A method of preparing an exosome containing one or more molecules to provide a therapeutic effect.
18 . The method of claim 17 , wherein the exosome is isolated from clonal progenitor cell line 30 MV2-14, 30-MV2-4, E69, or RPI-MV2-8.
19 . The method of claim 17 , wherein the exosome is capable of accelerating wound healing.
20 . The method of claim 17 , wherein the wound healing is measured by a migration assay and the percent of relative wound density is accelerated over that of a control without added exosomes.
21 . The method of claim 17 , wherein the exosome is capable of accelerating angiogenesis.
22 . The method of claim 17 , wherein the angiogenesis is observed by tube formation within 14 days.
23 . The method of claim 17 , wherein the exosome is loaded with miRNA.
24 . The method of claim 23 , wherein the miRNA is loaded via electroporation.
25 . The method of claim 17 , wherein the exosome is capable of providing epigenetic rejuvenation.
26 . The method of claim 17 , wherein the exosome is capable of modulating senolytic activity.
27 . The method of claim 17 , wherein the exosome is capable of cardioprotection.
28 . The method of claim 17 , wherein the exosome is capable of neuroprotection.
29 . The method of claim 17 , wherein the exosome is capable of cardiac repair or regeneration.
30 . The method of claim 17 , wherein the exosome is capable of regulating immune activity.
31 . The method of claim 17 , wherein the exosome is capable of reducing the effects of aging.
32 . The method of claim 17 , wherein the exosome is capable of increasing vaccine outcome or vaccine potency.